KRAS and cancer: Recent advances in medicinal chemistry have identified a binding pocket in the glycine-to-cysteine missense mutant KRAS protein at amino acid 12 (G12C), which comprises approximately 12% of all KRAS cancer mutations and accounts for a substantial fraction of KRAS mutations in non-small cell lung cancer (13%), and to a lesser degree in colorectal (4%) and pancreatic cancers (1–3%) [4,8–11].